amrinone has been researched along with prazosin in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ruggie, N | 1 |
| Medina, N; Packer, M; Yushak, M | 1 |
| Larbig, D; Nasse, H | 1 |
| Benotti, JR; Braunwald, E; Carabello, BA; Colucci, WS; Grossman, W; Malacoff, R; Rude, RE; Wynne, J | 1 |
| Heintz, B; Kirsten, D; Kirsten, R; Nelson, K | 1 |
3 review(s) available for amrinone and prazosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Congestive heart failure.
Topics: Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosides; Cardiotonic Agents; Diuretics; Dobutamine; Dopamine; Heart Failure; Humans; Hydralazine; Milrinone; Nitrates; Nitroprusside; Prazosin; Pyridones; Sympathomimetics; Vasodilator Agents | 1986 |
Clinical pharmacokinetics of vasodilators. Part II.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Alprostadil; Amrinone; Carbazoles; Carvedilol; Enoximone; Female; Humans; Iloprost; Imidazoles; Indoramin; Isosorbide Dinitrate; Labetalol; Milrinone; Molsidomine; Nitroglycerin; Nitroprusside; Oxyfedrine; Pentaerythritol Tetranitrate; Phosphodiesterase Inhibitors; Piperazines; Prazosin; Pregnancy; Propanolamines; Pyridones; Theophylline; Trapidil; Vasodilator Agents | 1998 |
14 other study(ies) available for amrinone and prazosin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition.
Topics: Adult; Aged; Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Hyponatremia; Male; Middle Aged; Prazosin; Proline | 1984 |
[Alternatives to digitalis therapy].
Topics: Aminopyridines; Amrinone; Captopril; Catecholamines; Diuretics; Heart Failure; Humans; Hydralazine; Nitrates; Nitroprusside; Practolol; Prazosin; Prenalterol; Vasodilator Agents | 1983 |
Problems in assessment of new pharmacologic agents for the heart failure patient.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Cardiovascular Agents; Drug Evaluation; Energy Metabolism; Ethanolamines; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardium; Prazosin; Vasodilator Agents | 1981 |